Trial · NCT05616013
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 56 | |
| Overall Study | STARTED | Bimagrumab 10 mg/kg | 56 | |
| Overall Study | STARTED | Bimagrumab 30 mg/kg | 57 | |
| Overall Study | STARTED | Placebo + Semaglutide 1.0 mg | 56 | |
| Overall Study | STARTED | Placebo + Semaglutide 2.4 mg | 57 | |
| Overall Study | STARTED | Bimagrumab 10 mg/kg + Semaglutide 1.0 mg | 56 | |
| Overall Study | STARTED | Bimagrumab 10 mg/kg + Semaglutide 2.4 mg | 56 | |
| Overall Study | STARTED | Bimagrumab 30 mg/kg + Semaglutide 1.0 mg | 56 | |
| Overall Study | STARTED | Bimagrumab 30 mg/kg + Semaglutide 2.4 mg | 57 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Placebo | 55 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Bimagrumab 10 mg/kg | 56 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Bimagrumab 30 mg/kg | 57 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Placebo + Semaglutide 1.0 mg | 55 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Placebo + Semaglutide 2.4 mg | 56 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Bimagrumab 10 mg/kg + Semaglutide 1.0 mg | 56 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Bimagrumab 10 mg/kg + Semaglutide 2.4 mg | 55 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Bimagrumab 30 mg/kg + Semaglutide 1.0 mg | 56 | |
| Overall Study | Safety Analysis Population (Received at Least 1 Dose of Study Drug) | Bimagrumab 30 mg/kg + Semaglutide 2.4 mg | 55 | |
| Overall Study | COMPLETED | Placebo | 29 | |
| Overall Study | COMPLETED | Bimagrumab 10 mg/kg | 27 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05616013/flow